Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The study will be an open-label, Phase 1b study of R289 to determine tolerability and
preliminary efficacy in patients with LR MDS who are relapsed, refractory/resistant,
intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO),
thrombopoietin (TPO), luspatercept, or hypomethylating agents (HMAs) for MDS.